Cost of screening, out-of-pocket expenditure & quality of life for diabetes & hypertension in India.
Cost
complications
diabetes
hypertension
out-of-pocket expenditure
quality of life
screening
Journal
The Indian journal of medical research
ISSN: 0971-5916
Titre abrégé: Indian J Med Res
Pays: India
ID NLM: 0374701
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
medline:
3
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
The Government of India has initiated a population based screening (PBS) for noncommunicable diseases (NCDs). A health technology assessment agency in India commissioned a study to assess the cost-effectiveness of screening diabetes and hypertension. The present study was undertaken to estimate the cost of PBS for Type II diabetes and hypertension. Second, out-of-pocket expenditure (OOPE) for outpatient care and health-related quality of life (HRQoL) among diabetes and hypertension patients were estimated. Economic cost of PBS of diabetes and hypertension was assessed using micro-costing methodology from a health system perspective in two States. A total of 165 outpatients with diabetes, 300 with hypertension and 497 with both were recruited to collect data on OOPE and HRQoL. On coverage of 50 per cent, the PBS of diabetes and hypertension incurred a cost of ₹ 45.2 per person screened. The mean OOPE on outpatient consultation for a patient with diabetes, hypertension and both diabetes and hypertension was ₹ 4381 (95% confidence interval [CI]: 3786-4976), ₹ 1427 (95% CI: 1278-1576) and ₹ 3932 (95% CI: 3614-4250), respectively. Catastrophic health expenditure was incurred by 20, 1.3 and 14.8 per cent of patients with diabetes, hypertension and both diabetes and hypertension, respectively. The mean HRQoL score of patients with diabetes, hypertension and both was 0.76 (95% CI: 0.72-0.8), 0.89 (95% CI: 0.87-0.91) and 0.68 (95% CI: 0.66-0.7), respectively. The findings of our study are useful for assessing cost-effectiveness of screening strategies for diabetes and hypertension.
Sections du résumé
Background & objectives
The Government of India has initiated a population based screening (PBS) for noncommunicable diseases (NCDs). A health technology assessment agency in India commissioned a study to assess the cost-effectiveness of screening diabetes and hypertension. The present study was undertaken to estimate the cost of PBS for Type II diabetes and hypertension. Second, out-of-pocket expenditure (OOPE) for outpatient care and health-related quality of life (HRQoL) among diabetes and hypertension patients were estimated.
Methods
Economic cost of PBS of diabetes and hypertension was assessed using micro-costing methodology from a health system perspective in two States. A total of 165 outpatients with diabetes, 300 with hypertension and 497 with both were recruited to collect data on OOPE and HRQoL.
Results
On coverage of 50 per cent, the PBS of diabetes and hypertension incurred a cost of ₹ 45.2 per person screened. The mean OOPE on outpatient consultation for a patient with diabetes, hypertension and both diabetes and hypertension was ₹ 4381 (95% confidence interval [CI]: 3786-4976), ₹ 1427 (95% CI: 1278-1576) and ₹ 3932 (95% CI: 3614-4250), respectively. Catastrophic health expenditure was incurred by 20, 1.3 and 14.8 per cent of patients with diabetes, hypertension and both diabetes and hypertension, respectively. The mean HRQoL score of patients with diabetes, hypertension and both was 0.76 (95% CI: 0.72-0.8), 0.89 (95% CI: 0.87-0.91) and 0.68 (95% CI: 0.66-0.7), respectively.
Interpretations & conclusions
The findings of our study are useful for assessing cost-effectiveness of screening strategies for diabetes and hypertension.
Identifiants
pubmed: 37530305
pii: IndianJMedRes_2023_157_6_498_382829
doi: 10.4103/ijmr.IJMR_389_20
pmc: PMC10466497
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
498-508Références
Diabetes Care. 2007 Feb;30(2):252-6
pubmed: 17259490
Diabetes Care. 2002 Mar;25(3):458-63
pubmed: 11874930
BMJ Glob Health. 2017 Jun 26;2(2):e000259
pubmed: 29225927
Value Health. 2016 Dec;19(8):921-928
pubmed: 27987641
Health Qual Life Outcomes. 2010 Feb 04;8:18
pubmed: 20132542
Pharmacoecon Open. 2019 Sep;3(3):391-402
pubmed: 30783991
Osong Public Health Res Perspect. 2018 Aug;9(4):167-174
pubmed: 30159222
BMC Pregnancy Childbirth. 2018 Oct 3;18(1):390
pubmed: 30285669
Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):551-558
pubmed: 29958008
Pharmacoecon Open. 2018 Jun;2(2):179-190
pubmed: 29623618
Qual Life Res. 2011 Aug;20(6):939-43
pubmed: 21221816
Pharmacoecon Open. 2018 Mar;2(1):1-3
pubmed: 29464668
Appl Health Econ Health Policy. 2020 Oct;18(5):699-711
pubmed: 32170666
J Diabetes Complications. 2010 Mar-Apr;24(2):84-9
pubmed: 19282203
Appl Health Econ Health Policy. 2017 Oct;15(5):681-692
pubmed: 28409489
Value Health Reg Issues. 2020 May;21:226-229
pubmed: 32330864
Value Health. 2006 Jan-Feb;9(1):47-53
pubmed: 16441524
Pharmacoecon Open. 2020 Jun;4(2):249-261
pubmed: 31468323
Front Cardiovasc Med. 2017 Nov 06;4:69
pubmed: 29164136
Int J Health Plann Manage. 2019 Jan;34(1):277-293
pubmed: 30113728
Lancet. 2003 Jul 12;362(9378):111-7
pubmed: 12867110
PLoS One. 2012;7(8):e44526
pubmed: 22952989